Cogent Biosciences, Inc.
bezuclastinib
GIST who have received prior treatment with imatinib
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on bezuclastinib for GIST who have received prior treatment with imatinib is in focus around Date TBD.
Primary source
· SEC 8-K
verified 15h ago
“Bezuclastinib - Expanded Access Program Working with the FDA, Cogent has established active Expanded Access Programs (EAPs) for U.S. patients with GIST or SM who meet disease-specific criteria and could benefit from treatment with bezuclast”